pleas
cite
articl
winhusen
lofwal
jone
et
al
medic
treatment
opioid
use
disord
expect
mother
mom
design
consider
pragmat
random
trial
compar
extendedreleas
daili
buprenorphin
formul
contemporari
clinic
trial
http
doi
opioidus
epidem
us
associ
signific
increas
preval
pregnant
women
opioid
use
disord
oud
infant
diagnos
neonat
opioid
withdraw
syndrom
now
now
result
physic
depend
inutero
opioid
caus
prolong
deliveri
hospit
increas
health
care
cost
nation
guidanc
recommend
pregnant
women
oud
maintain
methadon
sublingu
buprenorphin
bupsl
rel
methadon
bupsl
offer
advantag
lower
now
sever
infant
greater
conveni
pregnant
women
remov
requir
neardaili
clinic
visit
dose
bupsl
limit
includ
risk
divers
potenti
nonadher
poor
retent
daili
peaktrough
effect
evid
bupmaintain
pregnant
women
may
subtherapeut
dose
dose
interv
extendedreleas
xr
formul
address
disadvantag
bupsl
includ
nonadher
divers
potenti
peaktrough
issu
addit
pk
profil
bupxr
may
reduc
now
sever
rel
bupsl
specif
evid
peaktotrough
fluctuat
opioidmainten
may
increas
now
sever
bupxr
lower
peak
higher
trough
rel
bupsl
thu
result
lower
now
sever
moreov
higher
infant
norbuprenorphin
level
associ
greater
now
sever
firstpass
metabol
bup
norbuprenorphin
time
lower
bupxr
rel
bupsl
thu
predict
infant
norbuprenorphin
now
sever
lower
bupxr
possibl
disadvantag
bupxr
rel
bupsl
higher
medic
cost
howev
cost
may
justifi
j
u
r
n
l
p
r
e
p
r
f
cost
offset
exampl
associ
reduc
util
nowsrel
servic
anoth
possibl
disadvantag
bupxr
includ
differ
nonact
ingredi
includ
bupsl
potenti
impact
fetal
exposur
bupxr
yet
evalu
evalu
effect
bupxr
rel
bupsl
mother
infant
outcom
nation
drug
abus
treatment
clinic
trial
network
ctn
develop
studi
addit
first
trial
evalu
bupxr
pregnant
women
distinct
featur
includ
one
multisit
random
control
trial
rct
medic
oud
conduct
pregnant
women
provid
activ
treatment
women
month
postpartum
trial
also
uniqu
use
pragmat
featur
possibl
improv
real
world
applic
address
import
research
gap
manner
overburden
particip
main
studi
particip
invit
requir
particip
two
substudi
evalu
mechan
bupxr
may
improv
mother
infant
result
clinic
practic
given
dearth
evid
upon
base
clinic
guidanc
document
present
trial
design
protect
intern
valid
use
random
otherwis
favor
extern
valid
note
ford
norri
pragmat
trial
typic
pragmat
dimens
mom
follow
suggest
util
pragmat
featur
feasibl
still
maintain
trial
qualiti
abil
answer
question
interest
rational
key
design
decis
relat
main
trial
provid
two
bupxr
product
develop
recent
braeburn
pharmaceut
indivior
subcutan
inject
form
gel
deposit
releas
bup
steadi
rate
approxim
one
month
product
also
avail
weekli
formul
receiv
fda
approv
fda
determin
met
safeti
efficaci
standard
necessari
approv
approv
market
due
exclus
issu
avail
us
decemb
monthli
formul
contain
nmp
excipi
anim
studi
suggest
could
advers
fetaldevelopment
effect
weekli
product
includ
nmp
thu
select
bupxr
medic
mom
specif
weekli
product
util
particip
pregnant
breastfeed
monthli
formul
util
postpartum
phase
women
breastfeed
weekli
product
includ
three
excipi
phosphatidylcholin
glycerol
dioleat
gdo
ethanol
maximum
potenti
exposur
excipi
participantfetu
pregnanc
participantbreastfeed
infant
postpartum
calcul
phosphatidylcholin
may
offer
health
benefit
pregnanc
cholin
supplement
mgday
pregnanc
recommend
institut
medicin
american
medic
associ
total
possibl
maximum
exposur
pregnanc
would
gram
less
gram
would
consum
take
recommend
supplement
mgday
total
possibl
maximum
exposur
postpartum
would
gram
compar
gram
mgday
supplement
continu
one
year
postpartum
second
excipi
gdo
diglycerid
natur
occur
human
plasma
diacylglycerol
gdo
signific
compon
wide
use
food
product
eg
mayonnais
salad
dress
margarin
ice
etc
total
possibl
maximum
exposur
pregnanc
would
gram
equat
less
one
tablespoon
total
possibl
maximum
exposur
postpartum
would
gram
equat
approxim
one
tablespoon
third
excipi
ethanol
consum
suffici
quantiti
pregnant
women
teratogen
effect
maximum
weekli
dose
bupxr
mg
contain
gram
ethanol
standard
alcohol
drink
us
contain
gram
ethanol
total
possibl
maximum
exposur
ethanol
pregnanc
would
gram
ie
ethanol
singl
standard
drink
although
level
alcohol
exposur
consid
safe
pregnanc
potenti
substanti
benefit
bupxr
rel
bupsl
eg
superior
pk
profil
elimin
divers
potenti
improv
adher
justifi
theoret
risk
neglig
amount
subcutan
inject
ethanol
alcohol
use
encourag
breastfeed
women
cdc
note
moder
alcohol
use
standard
drink
per
day
known
harm
infant
maximum
possibl
total
postpartum
exposur
would
gram
ethanol
singl
standard
drink
thu
riskbenefit
ratio
postpartum
use
also
justifi
particip
random
bupsl
receiv
buprenorphin
without
bupsl
naloxon
bupnxsl
primari
rational
allow
medic
avoid
discourag
sitepati
particip
requir
use
medic
inconsist
site
prefer
addit
allow
medic
consist
goal
maintain
pragmat
design
feasibl
note
nguyen
colleagu
bupsl
commonli
use
pregnant
women
base
princip
limit
fetal
exposur
addit
compound
potenti
induc
withdraw
bupnxsl
inject
bupsl
like
divert
misus
bupnxsl
exist
literatur
rel
safeti
util
bupnxsl
pregnanc
limit
retrospect
chart
review
gener
found
evid
wors
outcom
bupnxsl
except
recent
studi
found
rate
prematur
low
birth
weight
higher
expect
addit
retrospect
studi
sampl
size
limit
ie
anticip
least
three
approxim
site
util
bupnxsl
henc
estim
minimum
mom
particip
take
bupnxsl
exploratori
analys
safeti
measur
compar
particip
take
bupsl
take
bupnxsl
pregnanc
perform
potenti
make
import
contribut
field
limit
evid
base
clinic
guidanc
document
treatment
oud
pregnant
women
consist
ctn
mission
trial
design
compar
effect
intervent
would
use
real
world
present
trial
protect
intern
valid
use
random
otherwis
favor
extern
valid
doubl
dummi
design
repres
standard
clinic
practic
would
artifici
remov
key
advantag
bupxr
avoid
daili
selfadministr
henc
mom
openlabel
trial
potenti
bia
result
openlabel
design
minim
mani
outcom
measur
includ
primari
key
secondari
outcom
util
lab
result
medic
record
abstract
pragmat
trial
minim
research
assess
sinc
reduc
generaliz
studi
result
real
world
practic
howev
goal
must
balanc
need
close
monitor
safeti
given
mom
first
trial
evalu
bupxr
formul
pregnant
women
balanc
achiev
includ
weekli
medic
check
visit
includ
minim
number
clinic
safeti
assess
procedur
limit
intens
data
collect
research
visit
occur
less
frequent
see
figur
bupxr
may
improv
outcom
rel
bupsl
due
superior
pk
profil
howev
consist
design
phase
trial
mom
util
nonj
u
r
n
l
p
r
e
p
r
f
journal
preproof
inferior
design
find
noninferior
would
suggest
bupxr
reason
altern
bupsl
thu
expand
avail
treatment
option
find
import
present
number
bup
provid
insuffici
meet
treatment
need
particularli
rural
area
signific
concern
clinician
unwil
prescrib
bupsl
potenti
divers
remov
barrier
would
thu
potenti
increas
avail
treatment
variabl
deliveryhospit
approach
now
could
advers
impact
evalu
effect
bup
treatment
arm
now
sever
key
secondari
measur
hand
primari
outcom
measur
mom
illicit
opioid
use
pregnanc
attempt
standard
now
scoringtreat
deliveri
hospit
particip
trial
studi
site
would
conflict
overal
goal
util
pragmat
featur
feasibl
resolv
problem
plan
decreas
deliveri
hospit
variabl
without
requir
standard
score
treatment
recommend
base
review
literatur
well
consensu
now
expert
protocol
develop
team
particip
elig
plan
deliv
hospit
meet
follow
requir
written
protocol
manag
now
implement
standard
protocol
decreas
length
opioid
treatment
day
infant
length
stay
lo
use
adjunct
drug
therapi
offer
roomingin
infant
observ
now
roomingin
associ
decreas
need
pharmacolog
treatment
now
shorter
lo
send
infant
home
opioid
treatment
now
infant
now
sever
measur
total
number
opioid
treatment
day
assess
j
u
r
n
l
p
r
e
p
r
f
journal
preproof
hospit
medic
record
therefor
opioid
provid
home
would
captur
better
outcom
research
newborn
born
survey
use
assess
deliveri
hospit
meet
protocoldefin
standard
requir
postpartum
period
time
women
particularli
vulner
relaps
increas
risk
overdos
postpartum
period
exist
thu
provid
effect
treatment
time
critic
protocol
team
also
opinion
signific
benefit
would
gain
evalu
full
postpartum
year
better
understand
substanc
use
trajectori
treatment
adher
could
impact
infant
neurodevelopment
outcom
thu
decis
made
extend
activ
treatment
phase
month
postpartum
mom
studi
conduct
nida
ctn
real
world
clinic
set
assess
paasa
character
treatment
mom
site
site
characterist
use
covari
statist
analys
recruit
pregnant
women
oud
rct
challeng
help
ensur
adequ
recruit
potenti
studi
site
care
screen
help
ensur
adequ
pool
potenti
particip
site
select
process
site
ask
provid
number
pregnant
women
start
bupsl
site
prior
month
proport
women
deliv
hospit
meet
protocoldefin
standard
requir
see
section
site
provid
bup
pregnant
women
officebas
set
offer
bup
treatment
follow
deliveri
month
admit
enough
potenti
elig
women
meet
target
random
rate
per
month
elig
potenti
particip
criteria
includ
adequ
medic
staf
safe
effect
conduct
mom
trial
perform
prior
clinic
trial
sitepati
divers
commit
site
director
staff
site
select
involv
process
brief
site
interest
survey
distribut
ctn
node
pi
result
site
design
good
candid
site
good
candid
site
invit
complet
full
site
select
survey
along
gener
invit
ctn
larg
full
site
select
survey
receiv
site
invit
particip
telephon
interview
final
site
select
determin
studi
execut
committe
base
inform
obtain
written
survey
telephon
interview
common
reason
site
exclus
inadequ
enrol
bupslmaintain
pregnant
patient
minim
permut
block
random
approach
use
balanc
site
whether
particip
bupsl
time
random
ye
vs
ega
time
random
week
vs
week
ega
use
stratif
variabl
mother
trial
studi
particip
randomli
assign
receiv
either
bupxr
bupsl
present
state
vari
extent
cover
cost
bup
treatment
pregnant
postpartum
women
state
cover
cost
one
year
postpartum
other
cover
pregnanc
mom
evalu
effect
bupxr
rel
bupsl
model
state
would
univers
cover
cost
bup
treatment
month
postpartum
given
variabl
state
coverag
could
achiev
provid
bupxr
bupsl
cost
studi
particip
come
sever
dose
weekli
everi
monthli
formul
allow
individu
medic
plan
see
tabl
small
volum
inject
come
prefil
syring
safeti
devic
store
unrefriger
administ
subcutan
thin
needl
target
dose
mg
weekli
formul
mg
monthli
formul
site
provid
bupsl
product
request
site
request
monobup
product
provid
mg
mg
bup
tablet
site
request
combin
product
provid
buprenorphinenaloxon
film
mg
bupnaloxon
dose
site
may
request
form
bupsl
j
u
r
n
l
p
r
e
p
r
f
journal
preproof
eg
monobup
product
use
pregnanc
combin
product
use
postpartum
phase
target
dose
mg
daili
consist
samhsa
recommend
dose
pregnanc
actual
xror
slbup
dose
may
lower
higher
recommend
target
dose
determin
prescrib
clinician
induct
bupxr
particip
alreadi
treat
bupsl
safe
transit
correspond
dose
bupxr
see
tabl
particip
treat
bupsl
site
util
induct
set
eg
outpati
inpati
typic
use
bupsl
recommend
weekli
dose
patient
current
receiv
bupsl
time
random
mg
weekli
titrat
first
week
treatment
follow
test
dose
transmucos
bup
mg
administ
object
sign
mild
moder
withdraw
appear
test
dose
toler
without
precipit
withdraw
first
dose
weekli
mg
administ
addit
dose
mg
weekli
administ
day
first
dose
achiev
recommend
mg
weekli
dose
need
first
week
treatment
addit
mg
dose
weekli
administ
wait
least
hour
previou
inject
total
weekli
dose
mg
weekli
postpartum
period
elig
bupxr
particip
safe
transit
correspond
dose
monthli
see
tabl
bupsl
studi
site
clinic
practic
regularli
use
bupsl
treat
pregnant
women
oud
follow
relev
clinic
practic
state
guidelin
bupsl
induct
procedur
typic
use
site
util
ideal
pragmat
trial
measur
would
obtain
unobtrus
order
reduc
particip
burden
avoid
research
assess
interact
could
impact
outcom
thu
reduc
generaliz
result
real
world
practic
howev
outcom
obtain
particip
input
mom
design
reli
much
possibl
electron
health
record
ehr
data
collect
data
directli
particip
measur
reflect
import
outcom
tabl
display
schedul
assess
categori
ie
efficaci
safeti
health
econom
whether
collect
weekli
medic
check
visit
research
visit
deriv
ehr
avoid
illicit
opioid
use
key
purpos
provid
buprenorphin
pregnant
women
oud
bupsl
effect
reduc
illicit
opioid
use
phase
trial
reveal
superior
bupnxsl
proport
illicit
opioidneg
urin
sampl
nonpregn
adult
mom
use
proport
illicit
opioidneg
urin
sampl
pregnanc
primari
outcom
urin
sampl
collect
weekli
medic
check
visit
sampl
valid
check
temperatur
monitor
commerci
avail
adulter
test
case
temperatur
readingadulter
test
indic
nonvalid
sampl
attempt
made
obtain
second
urin
sampl
sampl
ship
central
lab
analysi
use
rapid
ud
system
urin
sampl
test
buprenorphin
norbuprenorphin
fentanyl
cocain
methamphetamin
score
miss
urin
sampl
imput
posit
illicit
opioid
consist
approach
taken
phase
trial
greater
likelihood
illicit
opioid
use
patient
engag
treatment
number
udss
expect
particip
differ
base
length
pregnanc
thu
number
udss
potenti
imput
also
differ
particip
studi
team
decid
forgo
selfreport
assess
substanc
use
order
minim
assess
burden
lengthi
trial
conduct
particip
sampl
ie
pregnant
postpartum
women
may
find
longer
visit
challeng
may
prone
underreport
substanc
use
given
potenti
repercuss
mandatori
report
requir
present
mani
state
mother
key
secondari
outcom
measur
postpartum
illicit
opioid
abstin
assess
similar
fashion
illicit
opioid
abstin
pregnanc
infant
key
secondari
outcom
measur
now
sever
assess
total
day
opioid
treatment
hospit
stay
definit
use
past
research
outcom
abstract
medic
record
matern
secondari
outcom
includ
drug
alcohol
abstin
assess
ud
opioid
crave
scale
kotelchuck
adequaci
prenat
care
util
index
short
opiat
withdraw
scalegossop
bup
medic
adher
pregnanc
month
postpartum
adher
bupxr
base
studi
record
bupxr
receipt
weekli
inject
score
day
adher
journal
preproof
monthli
inject
particip
consid
adher
day
adher
bupsl
defin
studi
record
show
bupsl
dispens
particip
selfreport
adher
assess
weekli
medic
check
visit
udss
posit
buprenorphinenorbuprenorphin
infant
secondari
outcom
includ
five
addit
nowsrel
outcom
use
opioid
medic
now
symptom
yesno
ye
medic
use
infant
hospit
lo
defin
infant
age
day
discharg
use
adjunct
medic
eg
phenobarbit
clonidin
now
score
assess
use
peak
score
applic
code
indic
now
yesno
outcom
includ
discharg
outcom
includ
custodi
eg
mother
rel
fosteradopt
famili
medic
discharg
eg
phenobarbit
clonidin
whether
open
case
child
protect
servic
yesno
version
age
stage
questionnair
third
edit
use
screen
development
issu
infant
valid
parentadminist
screen
use
throughout
world
deem
appropri
assess
infant
expos
opioid
utero
safeti
measur
collect
studi
visit
see
tabl
includ
advers
event
assess
inject
site
examin
bupxr
particip
hospit
anxieti
depress
scale
prior
concomit
medic
assess
opioid
overdos
track
assess
selfreport
infant
sedat
eg
wake
feed
difficulti
breath
etc
assess
selfreport
particip
feed
infant
breastmilk
j
u
r
n
l
p
r
e
p
r
f
journal
preproof
andor
formula
ehrderiv
safeti
measur
includ
advers
fetal
outcom
matern
deliveri
outcom
eg
deliveri
type
medic
complic
deliveri
etc
birthneonat
outcom
includ
measur
collect
newborn
eg
ega
head
circumfer
weight
length
etc
well
advers
birth
neonat
outcom
eg
major
birth
defect
need
resuscit
etc
main
health
econom
outcom
increment
costeffect
ratio
icer
cost
measur
accord
healthcar
sector
perspect
includ
formal
medic
cost
incur
system
behalf
particip
arm
infant
healthcar
servic
util
measur
treatment
servic
review
nonstudi
medic
servic
nmo
form
assess
use
therapi
issu
substanc
use
disord
outofpocket
healthcar
expenditur
type
insur
effect
measur
includ
qualityadjust
lifeyear
qali
abstin
year
operation
estim
proport
year
particip
abstin
opioid
base
ud
result
healthrel
qualiti
life
measur
use
patientreport
outcom
measur
inform
system
promi
prefer
propr
score
system
j
u
r
n
l
p
r
e
p
r
f
journal
preproof
primari
outcom
proport
illicit
opioidneg
urin
sampl
pregnanc
assess
signific
level
noninferior
recommend
fda
dearth
research
treatment
oud
pregnant
women
therefor
data
upon
base
noninferior
margin
howev
optima
studi
noninferior
trial
compar
bupnxsl
methadon
nonpregn
particip
util
primari
outcom
similar
mom
primari
outcom
ie
proport
opioidneg
udss
collect
time
weekli
medic
check
miss
udss
imput
posit
noninferior
margin
optima
trial
select
base
literatur
review
expert
input
given
vulner
natur
patient
popul
illicit
opioid
use
impact
health
mother
also
infant
select
slightli
conserv
margin
ie
margin
reflect
allow
slightli
less
effect
bupxr
given
superior
pk
profil
elimin
potenti
divers
noninferior
margin
use
primari
outcom
well
key
secondari
outcom
postpartum
illicit
opioid
abstin
power
analys
requir
estim
percent
udss
would
illicit
opioidneg
pregnanc
bupsl
group
mean
select
sampl
size
simul
base
studi
fischer
colleagu
found
median
percentag
urin
sampl
neg
illicit
opioid
entir
cours
pregnanc
bupsl
particip
simul
studi
conduct
assess
studi
power
given
noninferior
margin
object
sampl
size
simul
determin
whether
would
suffici
power
detect
margin
sampl
size
particip
differ
assumpt
regard
impact
three
factor
use
random
site
ega
bupsl
statu
random
simul
data
assum
random
alloc
treatment
arm
mean
bupsl
arm
assum
mean
bupxr
arm
assum
null
correspond
specif
noninferior
margin
altern
varianc
arm
fix
contribut
come
three
random
effect
captur
random
stratafactor
addit
random
error
result
simul
evalu
power
type
error
two
possibl
relationship
random
factor
outcom
given
tabl
note
varianc
due
random
error
random
factor
associ
outcom
hand
varianc
outcom
random
error
random
factor
associ
outcom
anticip
latter
situat
less
power
lower
type
error
rate
tabl
see
even
random
factor
associ
outcom
still
least
power
detect
noninferior
margin
signific
level
sampl
size
analyt
approach
use
primari
mother
key
secondari
outcom
noninferior
design
yield
follow
hypothes
mean
arm
noninferior
margin
j
u
r
n
l
p
r
e
p
r
f
journal
preproof
evalu
noninferior
signific
level
twosid
confid
interv
treatment
effect
calcul
use
mix
effect
model
treatment
arm
fix
effect
three
random
strata
random
effect
lower
limit
confid
interv
greater
ie
reject
null
hypothesi
conclud
noninferior
bupxr
bupsl
null
hypothesi
reject
superior
bupxr
bupsl
consid
involv
examin
twosid
confid
interv
treatment
effect
lower
limit
zero
conclud
bupxr
superior
bupsl
order
test
follow
need
adjust
multipl
event
distribut
assumpt
involv
mix
effect
model
met
like
altern
nonparametr
method
consid
model
quantil
regress
total
day
infant
opioid
treatment
obtain
medic
record
extens
covari
includ
model
infant
outcom
mother
infant
deliveryhospitallevel
sinc
outcom
measur
count
variabl
covari
requir
adjust
model
util
poisson
regress
treatment
effect
measur
regress
coeffici
treatment
assign
model
h
previous
mention
miss
ud
imput
posit
illicit
opioid
primari
key
secondari
mother
outcom
differ
imput
method
loosen
miss
random
assumpt
may
consid
measur
sensit
j
u
r
n
l
p
r
e
p
r
f
journal
preproof
studi
result
similar
sensit
analys
may
also
conduct
key
secondari
infant
outcom
binari
secondari
outcom
proport
infant
requir
opioid
medic
proport
medic
chart
code
indic
now
logist
regress
pearson
test
associ
anoth
appropri
method
use
assess
relationship
treatment
assign
continu
outcom
medic
adher
opioid
crave
pregnanc
infant
weight
deliveri
model
use
anova
appropri
altern
eg
quantil
regress
evalu
effect
bupxr
lastli
number
opioid
overdos
model
count
variabl
possibl
zeroinfl
use
poisson
zeroinfl
poisson
regress
four
icer
calcul
sinc
evalu
two
measur
effect
qali
abstin
year
two
time
period
interest
pregnanc
deliveri
entir
studi
period
individu
multivari
regress
combin
statist
method
recycl
predict
use
predict
mean
valu
resourc
categori
outcom
time
period
studi
arm
icer
confid
interv
estim
use
nonparametr
bootstrap
techniqu
within
multivari
framework
accept
curv
construct
use
paramet
obtain
bootstrap
illustr
probabl
bupxr
good
valu
rel
bupsl
differ
willingnesstopay
threshold
ie
costperqali
costperabstinentyear
accept
curv
j
u
r
n
l
p
r
e
p
r
f
journal
preproof
develop
regardless
statist
signific
individu
cost
effect
differ
given
increas
power
detect
joint
differ
cost
effect
oversight
provid
multipl
board
addit
singl
irb
univers
cincinnati
new
drug
applic
studi
drug
current
avail
commerci
studi
popul
ind
annual
report
submit
fda
protocol
also
review
approv
nida
ctn
protocol
review
board
expert
matern
neonat
care
final
independ
ctn
data
safeti
monitor
board
dsmb
examin
accumul
data
assur
protect
particip
safeti
studi
scientif
goal
met
dsmb
recommend
sponsor
nida
whether
support
continu
trial
evid
studi
procedur
chang
trial
halt
reason
relat
safeti
studi
particip
efficaci
treatment
studi
inadequ
trial
perform
eg
poor
recruit
studi
recruit
schedul
start
april
site
initi
delay
j
u
r
n
l
p
r
e
p
r
f
journal
preproof
dearth
research
upon
base
clinic
guidanc
treatment
pregnant
women
oud
mom
trial
ind
trial
compar
matern
infant
outcom
pregnant
women
oud
treat
bupxr
rel
bupsl
design
pragmat
featur
conduct
real
world
set
ensur
find
generaliz
clinic
set
trial
also
unusu
follow
women
month
postpartum
uniqu
design
yield
data
address
number
gap
care
oud
pregnant
women
includ
mechan
bup
treatment
affect
matern
infant
outcom
potenti
impact
bup
exposur
neurodevelop
trial
hold
great
promis
provid
impact
advanc
treatment
pregnant
postpartum
women
oud
children
